touchLearning Activities
"Europe remains committed to the global fight to end polio once and for all" Polio may be a distant memory for many in Europe, but the virus is far from gone. New data reveal that vaccine-derived poliovirus type 2 (VDPV2) was ...
Dr Amesika Nyaku and the touchINFECTIOUS DISEASES team are thrilled to welcome a new editorial board member, Dr Jon Salmanton-García (University of Cologne, Germany), specializing in infectious diseases in immunocompromised patients, with a particular focus on respiratory viral infections ...
Calling All Healthcare Teams… Friday 28th February is Rare Disease Day Medics for Rare Disease, a UK registered charity, is asking healthcare professionals and healthcare students from UK and beyond, to join forces, to help drive rare disease awareness ...
The Conference on Retroviruses and Opportunistic Infections (CROI) is the leading global meeting for HIV research, bringing together over 4,000 experts from around the world. It serves as a platform for researchers to translate laboratory and clinical discoveries into meaningful advancements ...
The American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) has introduced a new groundbreaking set of guidelines to enhance infection prevention in regional anesthesia and interventional pain medicine procedures. Developed over four years, these recommendations address infection ...
Medics4RareDiseases is evolving. We are excited to announce a refresh of our strategy, a relaunch of our branding and even a new name! The charity has grown beyond our highest expectations over the last five years. With this ...
The world can eliminate AIDS by empowering communities and prioritizing human rights. We can end AIDS as a global health threat by 2030. The World Health Organization (WHO) joined forces with partners and communities to commemorate World AIDS Day 2024 (1 December), ...
Mpox is endemic in the Democratic Republic of the Congo (DRC), with cases rising over the past decade. Children were the most severely affected in the 2023 outbreak, which saw over 14,000 cases and 600 deaths.1 Despite the deployment of the modified vaccinia ...
touchINFECTIOUS DISEASES were thrilled to speak with Professor Barbara Van Der Pol (Professor of Medicine and Public Health, University of Alabama at Birmingham, AL) about her perspectives on recent advances in sexually transmitted infection (STI) diagnostic tools, management and breaking ...
As 2024 draws to a close, we’re celebrating a wonderful year of content. From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the infectious diseases community with high-quality, easily accessible content.
In this episode, we explore how point-of-care testing is transforming the management of sexually transmitted infections (STIs). Joined by Dr Libby van Gerwen, we discuss the rising global STI rates and the role these innovative tests play in addressing the issue. We also explore the challenges current point-of-care tests face and how next-generation advancements could further transform the future of STI diagnosis and treatment.
The start-to-finish of vaccines: Innovation and challenges at the World Vaccine Congress Europe 2024
The European Region is a global vaccine leader, boasting a “strong research ecosystem” and a competitive market, expected to achieve a volume of €16.32 billion by 2029. Through efforts to keep pace with the “unprecedented acceleration” of life science innovation, the landscape attracts investment and political support as leaders recognise the value of vaccination as a cost-effective intervention and a means of demonstrating health leadership.
In a real-world study from Ontario, researchers confirmed that a single dose of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine offers 58% protection against mpox infection.
Topline results from phase III PURPOSE 1 trial (NCT04994509) demonstrate the twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, achieved 100% efficacy in preventing HIV infections in cisgender women.
A recent study published in Science Advances highlights significant and unequal declines in life expectancy in India during the COVID-19 pandemic.
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) hosted its 2024 Global Congress in Barcelona, continuing its tradition of presenting high-quality data and fostering insightful discussions.
touchINFECTIOUS DISEASES
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
